Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
6.62
-0.15 (-2.22%)
Apr 8, 2026, 10:13 AM EDT - Market open
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 49 employees as of December 31, 2025. The number of employees increased by 16 or 48.48% compared to the previous year.
Employees
49
Change (1Y)
16
Growth (1Y)
48.48%
Revenue / Employee
n/a
Profits / Employee
-$838,918
Market Cap
416.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 49 | 16 | 48.48% | 49 | 0 |
| Dec 31, 2024 | 33 | 4 | 13.79% | 33 | 0 |
| Dec 31, 2023 | 29 | 8 | 38.10% | 29 | 0 |
| Dec 31, 2022 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2021 | 21 | 9 | 75.00% | 19 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Ginkgo Bioworks Holdings | 485 |
| Absci | 140 |
| Sutro Biopharma | 137 |
| Nautilus Biotechnology | 130 |
| Enanta Pharmaceuticals | 120 |
| Aura Biosciences | 113 |
| Century Therapeutics | 78 |
EPRX News
- 15 days ago - Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst - Benzinga
- 26 days ago - Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire
- 6 weeks ago - Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - Eupraxia Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire